Top News

May 05, 2017
By BioPharm International Editors
Forecasts were lowered, Reuters reported, due to reduced drug approvals and increased competitive pressures.
May 05, 2017
By BioPharm International Editors
The program aims to make biosimilars for the treatment of cancer more widely available in middle- and low-income countries.
Apr 21, 2017
The agency approved Renflexis, a biosimilar to Janssen’s blockbuster rheumatoid arthritis treatment.
Apr 13, 2017
UC Berkeley appealed the February 2017 decision that determined Harvard and MIT’s Broad Institute and Berkeley’s CRISPR-Cas9 technologies were separately patentable.
Mar 29, 2017
The mAb is the first approved treatment that targets the progressive form of the disease.
Mar 16, 2017
By BioPharm International Editors
Human antibody for Zika virus could help in the treatment and prevention of the infection.
Mar 13, 2017
Trump’s choice for FDA commissioner faces drug pricing, regulatory, and approval challenges.
Mar 10, 2017
The White House said President Trump will nominate Scott Gottlieb to the position of FDA commissioner.
Mar 02, 2017
The Mutual Recognition Agreement will allow FDA and EU inspectors to recognize each other’s work and avoid the duplication of drug inspections.
Feb 16, 2017
The Patent Trial and Appeal Board ruled in favor of the Broad Institute, allowing the institution to keep patents for its CRISPR-Cas9 gene-editing technology.
lorem ipsum